The estimated Net Worth of Elizabeth Ann Tarka is at least $19.8 mil dollars as of 25 March 2021. Elizabeth Tarka owns over 5,018 units of Idera Pharmaceuticals stock worth over $5,692 and over the last 5 years he sold IDRA stock worth over $14,086. In addition, he makes $0 as Senior Vice President e Chief Medical Officer at Idera Pharmaceuticals.
Elizabeth has made over 2 trades of the Idera Pharmaceuticals stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 5,018 units of IDRA stock worth $6,774 on 25 March 2021.
The largest trade he's ever made was selling 5,018 units of Idera Pharmaceuticals stock on 25 March 2021 worth over $6,774. On average, Elizabeth trades about 1,353 units every 15 days since 2019. As of 25 March 2021 he still owns at least 13,237 units of Idera Pharmaceuticals stock.
You can see the complete history of Elizabeth Tarka stock trades at the bottom of the page.
Dr. Elizabeth Ann Tarka M.D. serves as Senior Vice President, Chief Medical Officer of the Company. Prior to Complexa, Inc., Dr. Tarka served as Clinical Program Lead, Clinical Development at Janssen Pharmaceuticals, Inc. from September 2015 to September 2017, where she was the Clinical Program Leader for Xarelto® (rivaroxaban) and was responsible for the design, implementation and medical oversight for large multinational trials. Dr. Tarka held roles of increasing responsibility in late state clinical development of cardiovascular medications at GlaxoSmithKline from May 2003 to May 2015 and held the role of Senior Director, Clinical Development at the time of her transition to Janssen. Dr. Tarka earned her B.A. in Biochemistry and an M.D. from the University of Pennsylvania where she also completed her Internal Medicine residency and Cardiovascular fellowship training. She was also an Assistant Professor of Medicine in the Cardiovascular Division at the University of Pennsylvania where she had numerous major teaching and clinical responsibilities.
Elizabeth's mailing address filed with the SEC is 505 EAGLEVIEW BOULEVARD, SUITE 212, EXTON, PA, 19341.
Over the last 17 years, insiders at Idera Pharmaceuticals have traded over $20,746,904 worth of Idera Pharmaceuticals stock and bought 38,459,430 units worth $53,771,070 . The most active insiders traders include Bros. Advisors Lp14159, L.P..., Bros. Advisors Lp Baker Bro..., eInvest Corp Pillar Pharmace.... On average, Idera Pharmaceuticals executives and independent directors trade stock every 43 days with the average trade being worth of $309,429. The most recent stock trade was executed by John J. Kirby on 17 December 2021, trading 10,000 units of IDRA stock currently worth $6,200.
Harnessing the approach of the earliest researchers in immunotherapy and the company's vast experience in developing proprietary immunology platforms, Idera's development program is focused on priming the immune system to play a more powerful role in fighting cancer, ultimately increasing the number of people who can benefit from immunotherapy. Idera also continues to focus on the acquisition, development, and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined patient populations with serious unmet needs.
Idera Pharmaceuticals executives and other stock owners filed with the SEC include: